Stent-based tempamine delivery on neointimal formation in a porcine coronary model

Acute Cardiac Care

Volumn 8, Issue 4, 2006, Pages 210-216

  Huang, Yanming ^a,b,d   Wang, Lan ^a,c   Li, Shengqiao ^a   Liu, Xiaoshun ^a   Lee, Kwangdeok ^d   Verbeken, Eric ^a   Van De Werf, Frans ^a   De Scheerder, Ivan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Xiehe Hospital   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Restenosis; Stent; Tempamine

Indexed keywords

ELASTOMER; N,N,N TRIMETHYLTEMPAMINE; NITROXIDE DERIVATIVE; POLYAMIDE; POLYESTER; POLYMER; STAINLESS STEEL;

ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY STENT; FEMALE; HISTOPATHOLOGY; INFLAMMATION; INTIMA; MALE; MATERIAL COATING; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; SWINE; TISSUE REACTION;

ANALYSIS OF VARIANCE; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CYCLIC N-OXIDES; DRUG DELIVERY SYSTEMS; MICROSCOPY, ELECTRON, SCANNING; POLYMERS; STAINLESS STEEL; STENTS; SWINE; TUNICA INTIMA;

EID: 33845633614     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940600949661     Document Type: Article

References (27)

1. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-93.
2. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-95.
3. Morice MC, Serruys PW, Sousa JE, et al. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
4. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv. 2003;60:172-8.
5. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-45.
6. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106:2649-51.
7. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-86.
8. Virmani R, Kolodgie FD, Farb A, et al. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89:133-8.
9. Lee SH, Szinai I, Carpenter K, et al. In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. Coron Artery Dis. 2002;13:237-41.
10. Durand E, Al Haj Zen A, Addad F, et al. Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty. J Vasc Res. 2005;42:255-65.
11. Tardif JC, Gregoire J, L'Allier PL. Prevention of restenosis with antioxidants: mechanisms and implications. Am J Cardiovasc Drugs. 2002;2:323-34.
12. Wang L, Salu K, Verbeken E, et al. Stent-mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation. Coron Artery Dis. 2005;16:237-43.
13. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-74.
14. Huang Y, Wang L, Verweire I, et al. Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents. J Invasive Cardiol. 2002;14:505-13.
15. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-97.
16. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart. 2000;83:338-45.
17. Holmes DR, Camrud AR, Jorgenson MA, et al. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol. 1994;24:525-31.
18. Nunes GL, Robinson K, Kalynych A, et al. Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation. 1997;96:3593-601.
19. Azevedo LC, Pedro MA, Souza LC, et al. Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc Res. 2000;47:436-45.
20. Raikov ZD, Raikova ET, Atanasov AT. Nitric oxide and free stable nitroxyl radicals in the mechanism of biological action of the spin-labeled compounds. Med Hypotheses. 2001;57:302-5.
21. Swartz HM, Sentjurc M, Morse PD 2nd. Cellular metabolism of water-soluble nitroxides: effect on rate of reduction of cell/nitroxide ratio, oxygen concentrations and permeability of nitroxides. Biochim Biophys Acta. 1986;888:82-90.
22. Komarov AM, Joseph J, Lai CS. In vivo pharmacokinetics of nitroxides in mice. Biochem Biophys Res Commun. 1994;201:1035-42.
23. Hahn SM, Mitchell JB, Shacter E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med. 1997;23:879-84.
24. Zacharowski K, Olbrich A, Cuzzocrea S, et al. Membranepermeable radical scavenger, tempol, reduces multiple organ injury in a rodent model of gram-positive shock. Crit Care Med. 2000;28:1953-61.
25. Samuni A, Winkelsberg D, Pinson A, et al. Nitroxide stable radicals protect beating cardiomyocytes against oxidative damage. J Clin Invest. 1991;87:1526-30.
26. Gariboldi MB, Lucchi S, Caserini C, et al. Antiproliferative effect of the piperidine nitroxide TEMPAMINEL on neoplastic and nonneoplastic mammalian cell lines. Free Radic Biol Med. 1998;24:913-23.
27. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-9.